VIMS Print and Fly: AFGHANISTAN
|
|
- Gilbert Nichols
- 6 years ago
- Views:
Transcription
1 WHO Region: EMRO World Bank Income Group: Low-income GAVI Eligible: Countries in WHO Region: GAVI Phase III Eligible AFGHANISTAN, BAHRAIN, DJIBOUTI, EGYPT, IRAN, ISLAMIC REPUBLIC OF, IRAQ, JORDAN, KUWAIT, LEBANON, LIBYAN ARAB JAMAHIRIYA, MOROCCO, OMAN, PAKISTAN, QATAR, SAUDI ARABIA, SOMALIA, SUDAN, SYRIAN ARAB REPUBLIC, TUNISIA, UNITED ARAB EMIRATES, YEMEN Demographics & Disease Burden Indicator Value Year Population (thousands) 28, Birth Cohort (thousands) 1, Surviving Infants (thousands) 1, <5 Population (thousands) 5, Infant Mortality Rate (per 1000 live births) <5 Mortality Rate (per 1000 live births) GNI per capita, Atlas method, US$ Expenditure on Health as % of Total Government Expenditure Hib Death Rate (per 100,000 <5) S. pneumoniae Death Rate (per 100,000 <5) Rotavirus Death Rate (per 100,000 <5) %DTP3 Coverage Estimates: Years DTP Generated by VIMS on: 10/09/2013 1
2 Immunization Data: National Immunization Schedule: Vaccine Bacille Calmette-Guérin vaccine (BCG) Diphtheria and tetanus toxoid with whole cell pertussis, Hib and HepB (DTwPHibHep) Measles Oral Polio Vaccine (OPV) Pneumococcal conjugate vaccine (Pneumo_conj) Schedule birth; 6, 10, 14 weeks; 9, 18 months; birth; 6, 10, 14 weeks; 9 months; 6, 10, 14 weeks; Tetanus toxoid (TT) 1st contact; +1, +6 months; +1, +1 year; Generated by VIMS on: 10/09/2013 2
3 Introduction Status: Vaccine Status Program Type Planned Introduction Hib Pneumo Hep B Introduced into national immunization program GAVI approved/approved with clarification Introduced into national immunization program Actual Introduction Universal 1/1/2009 (Exact) 1/11/2009 (Exact) None Universal 11/1/2013 (Day Unknown) Rota GAVI plan to apply None 1/1/2014 (Month Unknown) 1/1/2006 (Month Unknown) End Key Details: (Hib) Source: Hib Status Sheet April 2009 Key Details: (Pneumo) Key Details: (Hep B) Plans to introduce PCV13 in Nov Source: WHO Internal Source, 25 Sep 2013 'Start ' is actual completion date for universal regional introduction. Source: SIMS Status Sheet June 2009 Key Details: (Rota) Source: WHO Internal Source, 25 Sep 2013 Generated by VIMS on: 10/09/2013 3
4 Application History: Pneumo Vaccine Planned App Actual App Outcome Details 8/1/2012 Approved Fully approved in /1/2011 5/15/2011 Conditional Approval Planned application in next round (expected May 2011), for introduction in /1/2009 Planned application for 2009, now uncertain. Application History: Hib Vaccine Planned App Actual App Outcome Details 2/1/2008 Approved 9/1/2007 Conditional Approval 4/1/2007 Resubmission Requested waiver for co-financing. Application History: Rota Vaccine Planned App Actual App Outcome Details 1/1/2012 Plans to apply in the next round after May, 2011 Application History: Hep B Vaccine Planned App Actual App Outcome Details Generated by VIMS on: 10/09/2013 4
5 Relationship with GAVI Alliance: GAVI Funding Stream VIMS Print and Fly: AFGHANISTAN Year HSS ISS INS Hib Mono HepB Mono MenA Measles Pneumo Penta Tetra Yellow Fever CSO Vaccine Intro Grant 2000 $ $ $ $519,500 $519, $519,500 $1,026,500 $1,546, $1,039,000 $650,000 $1,689, $2,791,180 $6,178,912 $100,000 $9,070, $6,700,000 $2,850,620 $3,724,721 $13,275, $4,595,000 $4,726,000 $8,136,881 $100,000 $404,000 $17,961, $7,318,000 $9,195,088 $1,018,000 $17,531, $8,157,346 $1,410,000 $12,255,01 1 Totals $1,165,000 $22,987, $3,180,000 $8,282,115 $458,400 $11,920,515 TOTAL $29,950,34 6 $13,855,80 0 $1,676,500 $0 $0 $0 $0 $0 $37,869,09 5 $9,903,633 $0 $2,741,400 $504,000 $96,500,774 Other Active Donors in Country: AusAID, Austrian Development Agency, DANIDA, Finland Development Cooperation, German BMZ, JICA, Sida, SDC, DFID, USAID, IDRC, Finland Department for International Development Cooperation, AFD, GTZ, Dutch Development Cooperation, AECID, Poland's Development Cooperation, TIKA Co-Pay Table Start Year Category CoFinancing Obligation 2012 Low-income US$ 0.20 per dose (no annual increase) 2008 Fragile GAVI Grouping: Fragile. Country will pay 10 cents per dose of the 1st vaccine, and 15 cents per dose for 2nd and 3rd vaccines. Generated by VIMS on: 10/09/2013 5
6 Decision Makers & Key Government Information: Year(s) of Last DHS Survey: 2010 Latest cmyp: Year(s) of Last Government Change: 2004, 2005, 2009, 2010 Details: President Hamid KARZAI (7 December 2004), Presidential election last held on 20 August 2009 (next to be held in 2014) National Assembly election last held on 18 September 2010 (next election expected in 2015) Has this Country Ever Served on the GAVI Board? No If so, when? n/a Key Advisory Groups Interagency coordinating committee Regional Body Responsible for Recommendations on New Vaccines National Body Responsible for Recommendations on New Vaccines Details MOPH, SCA, UNICEF, WHO. Regional Technical Advisory Group (RTAG). Members: Not Available Technical Advisory Group on Afghanistan. Members: not available Generated by VIMS on: 10/09/2013 6
7 Methods: This report has been generated by the Vaccine Information Management System (VIMS) database developed and maintained at the Johns Hopkins Bloomberg School of Public Health for use by the International Vaccine Access Center (IVAC) and its affiliated projects and partners. VIMS provides a centralized, web-based warehouse for key information related to IVAC s work. Information was gathered from internationally recognized sources, such as UNICEF, World Health Organization, vaccine manufacturers, ministries of health and news media. Projected introduction dates for GAVI countries are taken from the most recent publicly available AVI Strategic Demand Forecast. For non-gavi countries, the World Health Organization and a variety of other sources are used. If you have run a Vaccine Experience Custom Report and used the "Historical" option, the GAVI eligibility status reflected will be the most recent status within the time window you selected. Information on a particular country s GAVI application status or projected introduction dates may be sensititve and is not for public circulation without prior consent from VIMS personnel. If data is used in a presentation, it should include a statement indicating this. Sources: GAVI Eligibility Status Demographic and Disease Burden Table Population (thousands) UN Population Division. World Population Prospects: The 2012 Revision. Last accessed July 2013 at Birth Cohort UN Population Division. World Population Prospects: The 2012 Revision. Last accessed July 2013 at <5 Population (thousands) UN Population Division. World Population Prospects: The 2012 Revision. Last accessed July 2013 at Infant Mortality Rate (per 1000 live births) UN Population Division. World Population Prospects: The 2012 Revision. Last accessed July 2013 at <5 Mortality Rate (per 1000 live births) UN Population Division. World Population Prospects: The 2012 Revision. Last accessed July 2013 at GNI per capita, Atlas method, US$ Expenditure on Health as % of Total Government Expenditure Death Rate due to Hib (per 100,000 <5) World Bank. Development Data and Statistics Last accessed Jan, 2013 at: World Health Organization. National Health Accounts: Global Health Expenditure Database. Accessed 19 Aug 2013 at: Watt J.P., Wolfson L.J., O'Brien K.L., Henkle E., Deloria-Knoll M., McCall N., Lee E., Levine, O.S., Hajjeh, R., Mulholland, K., Cherian, T. and the Hib and Pneumococcal Global Burden of Disease Study Team. Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates (2009) The Lancet, 374 (9693), pp Data set last accessed on February 10, 2013 located at: Generated by VIMS on: 10/09/2013 7
8 Death Rate due to Rotavirus (per 100,000 <5) World Health Organization. Estimated rotavirus deaths for children under 5 years of age: 2008, Last accessed on February 10, 2013 at: Death Rate due to S. pneumoniae (per 100,000 <5) O'Brien K.L., Wolfson L.J., Watt J.P., Henkle E., Deloria-Knoll M., McCall N., Lee E., Mulholland, K., Levine, O.S., Cherian, T. and the Hib and Pneumococcal Global Burden of Disease Study Team. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates (2009) The Lancet, 374 (9693), pp Data set last accessed on February 10, 2013 at: % of Under 5 deaths due to... World Health Organization. World Health Statistics Last accessed January, 2013 at: Surviving Infants (in thousands) National Immunization Schedule (Table) UNICEF. Immunization Summary (2013 Edition): A Statistical Reference Containing Data through Last accessed Feb, 2013 at: World Health Organization. WHO Vaccine-Preventable Diseases Monitoring System (Joint Reporting Form). Last updated 13 Jul Accessed 23 Aug 2013 at: % DTP1 and DTP3 Official Coverage (Table) WHO/UNICEF Estimates of National Immunization Coverage: 2012 Revision. (Country Reports). Data as of 30 Jun Accessed 21 Aug 2013 at: Introduction Status Table VIMS Print and Fly: AFGHANISTAN Gathered from various sources, such as the GAVI Alliance, WHO, UNICEF, ministries of health, the news media and IVAC partners/contacts. Introduction dates prior to 2000 rely primarily on: World Health Organization. Immunization Schedules Last accessed November 23, 2009 at Application History Table Communication with GAVI Alliance. Funding Summary Table Co-pay Table GAVI Disbursements by Country. GAVI Alliance. GAVI disbursements to countries by type of support and year (2000-September 30, 2012). Last accessed February 10, 2013 at We draw this information from a variety of sources; however, GAVI is our primary source. GAVI Cofinancing Policy Brief, August Decision Makers and Key Government Information Table Year of Most Recent DHS Survey Demographic and Health Surveys. Country List. Accessed 27 Aug 2013 at: Generated by VIMS on: 10/09/2013 8
9 Year of Most Recent cmyp Years of Last Government Change GAVI Board Membership (Has Country Ever Served on GAVI Board) Key Advisory Groups Other Active Donors in Country Country Visits Table World Health Organization. WHO Vaccine-Preventable Diseases Monitoring System (Joint Reporting Form Estimates). Last updated 14 Jul 2013, data as of 12 Jul Accessed 22 Aug 2013 at: CIA World Fact Book. CIA. Last accessed June 1, 2011 at GAVI Alliance. GAVI Board Members Last accessed August 2011 at We rely on a variety of sources, such as SIVAC, NITAG Resource Center, WHO, UNICEF, GAVI Alliance, ministries of health, the news media and IVAC partners/contacts. For more information, please contact vims@jhsph.edu. We rely on a variety of sources, such as SIVAC, NITAG Resource Center, WHO, UNICEF, GAVI Alliance, ministries of health, the news media and IVAC partners/contacts. For more information, please contact vims@jhsph.edu. This information comes from Trip Reports located in VIMS. Generated by VIMS on: 10/09/2013 9
10 Selected Key Words: Any definitions not provided below can be found in the Glossary located in the Help section in VIMS Introduced into national immunization program: the vaccine has been incorporated into the national government s immunization program, either for all children, an at-risk subset, or for a regional program and it may include programs that are being phased in over time. This status can apply to any country, regardless of GAVI eligibility. Regional: local government immunization programs, but the national government has not included the vaccine in its immunization program. Widespread coverage through private market: most (over half) of the target population is receiving the vaccine through private market use. Risk: program for this vaccine only covers children in specific high risk groups this may include children with health conditions, those of vulnerable socioeconomic statuses or ethnic groups, or those living in regions of high risk. GAVI approved/approved with clarification: the country s application to GAVI for New and Underused Vaccines Support (NVS) financing for this vaccine has been approved or approved with clarifications. Approved: the application meets all the criteria and is approved for GAVI support. Approved with clarifications: The application lacks specific pieces of data, which must be provided generally within a month. Data must be received before the application is considered officially approved for GAVI Support. GAVI conditional approval to introduce: The application to GAVI for New and Underused Vaccines Support (NVS) for this vaccine does not fulfil specific or significant application requirements. Missing requirements must be provided in a subsequent round to complement the original application. Conditional approvals will be valid for 12 months. If the conditions are not met within one year of the first submission, re-submission of a new application is required. GAVI Resubmission: The New and Underused Vaccines Support (NVS) application for this vaccine is incomplete and a full application should be submitted in a future round. GAVI application submitted under review: The country has submitted a New and Underused Vaccines Support (NVS) application for this vaccine and is awaiting GAVI evaluation. GAVI plan to apply: Country has made a public statement (through government or other recommending body on vaccines) that they plan to introduce the vaccine and apply for GAVI New and Underused Vaccines Support (NVS), but has not yet submitted an application. Non-GAVI Planning Introduction: A country which is not eligible for GAVI support has indicated plans to introduce the vaccine into its national immunization program, and has taken steps to initiate its program, such as contacting the vaccine manufacturer. No Decision: The country has not indicated a firm decision to introduce the vaccine into its national immunization program or to apply for GAVI New and Underused Vaccines Support (NVS) for the vaccine. Unknown: sources differ or are unclear on whether this country has a national program or not. Vaccine Licensed for Use in Country: At least one pneumococcal conjugate vaccine is licensed for use in children by the national vaccine regulatory agency in this country. Generated by VIMS on: 10/09/
VIEW-hub Report: Global Vaccine Introduction and Implementation
A report on current global access to new childhood vaccines VIEW-hub Report: Global Vaccine Introduction and Implementation September 2017 Developed from data in VIEW-hub www.view-hub.org Johns Hopkins
More informationVIEW-hub Report: Global Vaccine Introduction and Implementation
A report on current global access to new childhood vaccines VIEW-hub Report: Global Vaccine Introduction and Implementation December 2016 Developed from data in VIEW-hub www.view-hub.org Johns Hopkins
More informationThe Jordan University Hospital, Amman, Jordan
The Jordan University Hospital, Amman, Jordan Pneumococcal vaccine and overcoming the immunization rift Najwa Khuri-Bulos JUH Amman, Jordan February 13 2008 Pneumococcal disease burden 1.6 million deaths
More informationGAVI ALLIANCE: UPDATE AND FUTURE DIRECTIONS FOR GLOBAL VACCINES AND IMMUNISATIONS
GAVI ALLIANCE: UPDATE AND FUTURE DIRECTIONS FOR GLOBAL VACCINES AND IMMUNISATIONS Ranjana Kumar International Rotavirus Symposium Istanbul, 3 4 June 2008 The GAVI Alliance Public-private partnership bringing
More informationGlobal Health Policy: Vaccines
Global Health Policy: Vaccines Edwin J. Asturias Senior Investigator Colorado School of Public Health Department of Pediatrics Children s Hospital Colorado UNIVERSITY OF COLORADO COLORADO STATE UNIVERSITY
More informationProgress report on the achievement of the health-related Millennium Development Goals and global health goals after 2015
Regional Committee for the Eastern Mediterranean Fifty-ninth session Provisional agenda item 2 (c) EM/RC59/INF.DOC.3 July 2012 Progress report on the achievement of the health-related Millennium Development
More informationVIEW-hub Report: Global Vaccine Introduction and Implementation
A report on current global access to new childhood vaccines VIEW-hub Report: Global Vaccine Introduction and Implementation December 2016 INTERNAL VERSION Developed from data in VIEW-hub www.view-hub.org
More informationThe Financial Sustainability of New Vaccine Introduction in the Poorest Countries :
The Financial Sustainability of New Vaccine Introduction in the Poorest Countries : Evidence from the First Phase of GAVI (Global Alliance for Vaccines and Immunization) Patrick Lydon lydonp@who.int Session:
More informationAccess to vaccination in GAVI countries and at global level
Access to vaccination in GAVI countries and at global level Stefano Malvolti Director, Vaccine Implementation GAVI Alliance 15th ADVANCED COURSE OF VACCINOLOGY May 12, 2014 Global progress to MDG 4 for
More informationImmunization Update & focus on meningococcal vaccine PART 1
Immunization Update & focus on meningococcal vaccine PART 1 Gregory Hussey Vaccines for Africa Initiative Institute of Infectious Diseases University of Cape Town www.vacfa.uct.ac.za Disclosures Received
More informationExpanded Programme on Immunization (EPI)
Timor-Leste 217 Expanded Programme on Immunization (EPI) FACT SHEET Acronyms AD Auto disable MCV1 First dose measles containing vaccine AEFI Adverse events following immunization MCV2 Second dose measles
More informationEMRO May (EMVAP) Action
EMRO Framework for implementation Global Vaccine May Eastern Mediterr ranean Vaccine Action Plan 2016-2020 (EMVAP) A Framework for Implementation of Global Vaccine Action Plan (GVAP) Eastern Mediterranean
More informationAfghanistan: WHO and UNICEF estimates of immunization coverage: 2017 revision
Afghanistan: WHO and UNICEF estimates of immunization coverage: 2017 revision July 7, 2018; page 1 WHO and UNICEF estimates of national immunization coverage - next revision available July 15, 2019 data
More informationSyrian Programme Refugees Advice on assessment of immunisation status and recommendations for additional immunisation
Syrian Programme Refugees Advice on assessment of immunisation status and recommendations for additional immunisation Background Information Immunisation services in Syria Syria had good immunisation services,
More informationPakistan: WHO and UNICEF estimates of immunization coverage: 2017 revision
Pakistan: WHO and UNICEF estimates of immunization coverage: 2017 revision July 7, 2018; page 1 WHO and UNICEF estimates of national immunization coverage - next revision available July 15, 2019 data received
More informationThe Gates Challenge. Bill Gates Commencement Address Harvard University Class of 2007
History & Future of the Expanded Programme on Immunization Supplier Meeting, Copenhagen, 3-4 April 2008 Dr Osman David Mansoor Senior Adviser EPI (New Vaccines) UNICEF New York The Gates Challenge If we
More informationGAVI s Financing for Pneumococcal Vaccines, including the Advance Market Commitment
GAVI s Financing for Pneumococcal Vaccines, including the Advance Market Commitment Tania Cernuschi Third Regional Pneumococcal Symposium, Istanbul, 13th - 14th February 2008 1 The GAVI Alliance Public-private
More informationVaccine Introduction & Uptake Timing Benchmark Project
Vaccine Introduction & Uptake Timing Benchmark Project Lois Privor-Dumm Managing Director Policy, Advocacy & Communications Team Lead International Vaccine Access Center Johns Hopkins Bloomberg School
More informationWHO Health Statistics : Applied through the lens of the Global Monitoring Framework for the Prevention and Control of Noncommunicable Diseases
WHO Health Statistics : Applied through the lens of the Global Monitoring Framework for the Prevention and Control of Noncommunicable Diseases Dr E Tursan d'espaignet Prevention of Noncommunicable Diseases
More informationExpanded Programme on Immunization (EPI)
Sri Lanka 217 Expanded Programme on Immunization (EPI) FACT SHEET Acronyms AD Auto disable MCV1 First dose measles containing vaccine AEFI Adverse events following immunization MCV2 Second dose measles
More informationGAVI RESOURCE GAP ALWAYS BEEN AN ISSUE
GAVI RESOURCE GAP ALWAYS BEEN AN ISSUE 1 Phasing in (an early diagram) 5 year Vaccine Fund commitment extended over 8 year phase- Countries will be notified of 5 year Vaccine Fund commitment Investments
More informationExpanded Programme on Immunization (EPI)
Indonesia 217 Expanded Programme on Immunization (EPI) FACT SHEET Acronyms AD Auto disable MCV1 First dose measles containing vaccine AEFI Adverse events following immunization MCV2 Second dose measles
More informationNigeria: WHO and UNICEF estimates of immunization coverage: 2017 revision
Nigeria: WHO and UNICEF estimates of immunization coverage: 2017 revision July 7, 2018; page 1 WHO and UNICEF estimates of national immunization coverage - next revision available July 15, 2019 data received
More informationSummary of Definitions of Mission and Strategic Goal Level Indicators. in GAVI Alliance Strategy Updated October 2013
Summary of s of Mission and Strategic Goal Level Indicators in GAVI Alliance Strategy 2011-2015 Updated October 2013 Table of Contents Under five mortality rate ------------------------------------------------------------------------------------------------------------------------
More informationGLOBAL IMMUNIZATION COVERAGE IN 2016
NATIONAL IMMUNIZATION COVERAGE SCORECARDS ESTIMATES FOR 2016 GLOBAL IMMUNIZATION COVERAGE IN 2016 In May 2012, the Sixty-fifth World Health Assembly endorsed the Global Vaccine Action Plan (GVAP) for the
More informationVaccines. Global impact of a preventive technology. Edwin J. Asturias, MD
Vaccines Global impact of a preventive technology Edwin J. Asturias, MD Associate Professor of Pediatrics and Epidemiology Director for Latin America Center for Global Health, Colorado School of Public
More informationVaccines. Global impact of a preventive technology. Edwin J. Asturias, MD
Vaccines Global impact of a preventive technology Edwin J. Asturias, MD Associate Professor of Pediatrics and Epidemiology Director for Latin America Center for Global Health, Colorado School of Public
More informationEastern Mediterranean Region
Eastern Mediterranean Region I. Introduction The WHO Eastern Mediterranean Region comprises 23 countries. It has a population of 597 million people 1. It is a widely diversified region in which countries
More informationTask Force on Immunization (TFI) in Africa 14 th Annual Meeting. And. Africa Regional Inter-Agency Coordination Committee (ARICC) 13 th Annual Meeting
Task Force on Immunization (TFI) in Africa 14 th Annual Meeting And Africa Regional Inter-Agency Coordination Committee (ARICC) 13 th Annual Meeting Meeting Report Maputo, Mozambique 27 29 November 2006
More informationGavi s strategic framework 22 June 2016
Gavi s 2016 2020 strategic framework 22 June 2016 Gavi 2000-2015 Gavi 3.0 Gavi 2.0 250 million children immunised Gavi 1.0 90m children immunised 200 million children immunised 2000 2005 2006 2010 2011
More informationGlobal Health Policy: Vaccines
Global Health Policy: Vaccines Edwin J. Asturias Senior Investigator Colorado School of Public Health Department of Pediatrics Children s Hospital Colorado UNIVERSITY OF COLORADO COLORADO STATE UNIVERSITY
More informationTotal population 24,759,000. Live births (LB) 342,458. Children <1 year 337,950. Children <5 years 1,698,664. Children <15 years 5,233,093
DPR Korea 4 Immunization system highlights There is a comprehensive multiyear plan (cmyp) for immunization covering -5. A standing national technical advisory group on immunization (NTAGI) with formal
More informationEvaluating Immunisation Dropout Rates in Eight Hard to Reach Unions of Maulvibazar District, Bangladesh
International Journal of Immunology 2017; 5(1): 5-10 http://www.sciencepublishinggroup.com/j/iji doi: 10.11648/j.iji.20170501.12 ISSN: 2329-177X (Print); ISSN: 2329-1753 (Online) Evaluating Immunisation
More informationUpdate from GAVI Aurelia Nguyen
Update from GAVI Aurelia Nguyen (Copenhagen, Denmark, 27 June 2012) GAVI vaccine support Currently supported vaccines: pentavalent, pneumococcal, rotavirus, meningitis A, human papillomavirus (HPV), rubella,
More informationExpanded Programme on Immunization (EPI)
Bhutan 2017 Expanded Programme on Immunization (EPI) FACT SHEET Acronyms AD Auto disable MCV1 First dose measles containing vaccine AEFI Adverse events following immunization MCV2 Second dose measles containing
More informationAnnex 3. Meetings held in the Eastern Mediterranean Region, 2014
Annex 3. Meetings held in the Eastern Mediterranean Region, Statutory and advisory meetings Expanded meeting for members of the Advisory Committee on Health Research to discuss integrating research in
More informationPARTNERSHIP PROFILE: GAVI
PARTNERSHIP PROFILE: GAVI About the GAVI Alliance The GAVI Alliance (formerly the Global Alliance for Vaccines and Immunisation) was launched in 2000 as a global public-private partnership to improve access
More informationFrom development to delivery: Decision-making for the introduction of a new vaccine
From development to delivery: Decision-making for the introduction of a new vaccine Prince Mahidol Award Conference Bangkok, Thailand 1-2 February 2007 Dr. J.M. Okwo-Bele Department of Immunization, Vaccines
More informationReport to the Board 6-7 June 2018
Report to the Board 6-7 June 2018 SUBJECT: Category: PROGRAMME AND POLICY COMMITTEE CHAIR REPORT For Information Section A: Introduction This report provides the Board with an overview of the activities
More informationWHITE PAPER. A Summary of Global Immunization Coverage through David W Brown, Anthony H Burton, Marta Gacic-Dobo (alphabetical order)
WHITE PAPER A Summary of Global Immunization Coverage through 2013 David W Brown, Anthony H Burton, Marta Gacic-Dobo (alphabetical order) for the WHO and UNICEF working group for monitoring national immunization
More informationUpdate from the GAVI Alliance Seth Berkley, MD Chief Executive Officer
Update from the GAVI Alliance Seth Berkley, MD Chief Executive Officer SAGE meeting Geneva, 8-10 November 2011 Topics to cover Update on new vaccine introduction Introductions New approvals Co-financing
More informationProgrammatic Feasibility of Measles Elimination
Programmatic Feasibility of Measles Elimination World Health Organization Eastern Mediterranean Region June 2010 Acronyms: EMR Eastern Mediterranean Region of the World Health Organization 1 EMRO EPI GAVI
More informationyour liver Care for Think about hepatitis
your liver Care for Think about hepatitis World Hepatitis Day 2015 What is hepatitis? Hepatitis is the common name for all inflammatory diseases of the liver. Liver inflammation is most often caused by
More informationAcquired immuno-deficiency syndrome (AIDS) in the Eastern Mediterranean Region
WHO-EMlRC/INF.DOC. Acquired immuno-deficiency syndrome (AIDS) in the Eastern Mediterranean Region. Introduction By the end of 00, an estimated 0 million people in the world were living with HIV/AIDS, million
More informationSelected vaccine introduction status into routine immunization
Selected introduction status into routine infant immunization worldwide, 2003 This report summarizes the current status of national immunization schedules in 2003, as reported by Member States in the /UNICEF
More informationParadigm shift: from dependency to country ownership Seth Berkley, MD Chief Executive Officer of the GAVI Alliance
Paradigm shift: from dependency to country ownership Seth Berkley, MD Chief Executive Officer of the GAVI Alliance Sabin 20 th Anniversary Scientific Forum 25 April 2014 The GAVI Alliance: a public-private
More informationUNICEF Procurement Advancements DCVMN Annual Meeting Hanoi, Vietnam October 2013
UNICEF Procurement Advancements DCVMN Annual Meeting Hanoi, Vietnam October 2013 Presentation overview Scope of UNICEF procurement Overview of UNICEF procurement Vaccine market updates UNICEF procures
More informationEastern Mediterranean Region Framework for health information systems and core indicators for monitoring health situation and health system
Eastern Mediterranean Region Framework for health information systems and core indicators for monitoring health situation and health system performance 2017 Eastern Mediterranean Region Framework for
More informationTotal population 1,212,110. Live births (LB) 43,924. Children <1 year 40,351. Children <5 years 192,340. Children <15 years 510,594
Draft version for the SEAR-ITAG 5-9 June 5 All data provisional as of May 5 Timor Leste 4 Immunization system highlights There is a comprehensive multi-year plan (cmyp) for immunization covering 3-5. 8%
More informationUPDATE ON GAVI. Julian Lob-Levyt. Global Immunisation Meeting New York, February 2009
UPDATE ON GAVI Julian Lob-Levyt The GAVI Alliance Board structure GAVI Alliance Informal, not a legal entity Partner representatives Public sector expertise (plus vaccine industry) Programmatic oversight
More informationGUIDELINES FOR APPLICATIONS
GUIDELINES FOR APPLICATIONS New and Underused Vaccines Support 2013 Application Deadline: 15 September 2013 Document updated: 14 June 2013 This document replaces all previous versions. Important upcoming
More informationHarnessing the power of vaccines using the public and private sector: A 21 st century model for international development
Harnessing the power of vaccines using the public and private sector: A 21 st century model for international development Dr. Seth Berkley, CEO GAVI Alliance Wellcome Trust Cambridge Centre for Global
More informationVERSION APPROVAL PROCESS NUMBER 1.0 Nina Schwalbe, Managing Director, Policy and Performance
Version No.: 1.0 Page 1 / 5 DOCUMENT ADMINISTRATION VERSION APPROVAL PROCESS DATE NUMBER 1.0 Nina Schwalbe, Managing Director, and Performance Reviewed by: GAVI Programme 23 April 2012 and Committee Approved
More informationGlobal landscape analysis and literature review of 2 nd Year of Life immunization platform
Global landscape analysis and literature review of 2 nd Year of Life immunization platform Global Vaccine and Immunization Research Forum 15-17 March 2016 Johannesburg, South Africa Imran Mirza; Celina
More informationCEO Board report Seth Berkley MD CEO
CEO Board report Seth Berkley MD CEO Dhaka, Bangladesh, 16 17 November 2011 Bangladesh, November 2011 Meningitis Incidence Children < 12 months Dhaka Shishu / Shishu Shahsta Catchment Area 2008 2011 1800
More informationHistorical Analysis of the Comprehensive Multi-Year Plans in GAVI-Eligible countries ( )
Historical Analysis of the Comprehensive Multi-Year Plans in GAVI-Eligible countries (2004-2015) Joint Collaboration Between the Bill & Melinda Gates Foundation and the World Health Organization Revised
More information@GaviSeth. Report from Gavi. Seth Berkley, CEO Meeting of the Strategic Advisory Group of Experts on Immunization April
1 @GaviSeth Report from Gavi Seth Berkley, CEO Meeting of the Strategic Advisory Group of Experts on Immunization April 2016 www.gavi.org Why SAGE matters to Gavi Gavi relies on SAGE technical guidance
More informationShabir A. Madhi. Progress and Challenges of Immunization Contributing Toward Attaining the MDG Goal to Reduce under-5 Childhood Mortality.
Shabir A. Madhi Progress and Challenges of Immunization Contributing Toward Attaining the MDG Goal to Reduce under-5 Childhood Mortality. National Institute for Communicable Diseases & University of Witwatersrand,
More informationThe Johns Hopkins Vaccine Initiative Johns Hopkins Bloomberg School of Public Health
WHO Internships (Terms of Reference) for VIEW Scholars Program January 2010 A. Examining approaches to collecting and analyzing HPV vaccine coverage data B. County level burden of disease estimates for
More informationRegional & National Partnerships to Stop TB in the Eastern Mediterranean Region-lessons learnt
Regional & National Partnerships to Stop TB in the Eastern Mediterranean Region-lessons learnt Dr. Mohamed Awad Tag Eldin Chair, Coordinating Board of the Eastern Mediterranean Partnership to Stop TB Eastern
More informationEx post evaluation Tanzania
Ex post evaluation Tanzania Sector: Health, family planning, HIV/AIDS (12250) Project: Promotion of national vaccination programme in cooperation with GAVI Alliance, Phase I and II (BMZ no. 2011 66 586
More informationGAVI partners Forum, Dar es Salaam, Tanzania December 5-7, 2012
GAVI partners Forum, Dar es Salaam, Tanzania December 5-7, 2012 ADRESSING CHALLENGES TO SUSTAINABLE NEW VACCINE INTRODUCTION: PERSPECTIVE FROM MONGOLIA N.UDVAL, MD, Sc D MINISTER OF HEALTH MONGOLIA CONTENT
More informationThe global progress towards poliomyelitis
Communicable diseases Poliomyelitis eradication The global progress towards poliomyelitis eradication in 2014 was substantial. However, the disease remains endemic in the Region. Of the 215 polio globally
More informationKeynote Address: The Challenge of Achieving Universal Access to Vaccines
Keynote Address: The Challenge of Achieving Universal Access to Vaccines & AMF Seth Berkley M.D, CEO www.gavi.org 1 Vaccine landscape The world before vaccines Examples of major disease outbreaks Yellow
More informationSamir K Saha, Ph.D Child Health Research Foundation Dhaka Shishu Hospital Dhaka, Bangladesh
Barriers Rotavirus to Rotavirus Vaccine Impact Vaccine Beyond Preventing Introduction Diarrhea Samir K Saha, Ph.D Child Health Research Foundation Dhaka Shishu Hospital Dhaka, Bangladesh 13 th International
More information1. Executive Summary 2. Worldwide Pediatric Vaccines Market and Forecast ( ) 3. Worldwide Pediatric Vaccines Market Share & Forecast (Sector
1. Executive Summary 2. Worldwide Pediatric Vaccines Market and Forecast (2006 ) 3. Worldwide Pediatric Vaccines Market Share & Forecast (Sector wise) (2005 ) 4. Worldwide Pediatric Vaccines Market Share
More informationProgress report on. Eradication of poliomyelitis
Regional Committee for the EM/RC52/INF.DOC.2 Eastern Mediterranean August 2005 Fifty-second Session Original: Arabic Agenda item 4 (b) Progress report on Eradication of poliomyelitis Contents 1. Introduction...1
More informationPresentation to 13th Annual General Meeting of the DCVMN UNICEF Vaccine Forecasting
Presentation to 13th Annual General Meeting of the DCVMN UNICEF Vaccine Forecasting 1 November 2012 Deaths among children under 5 globally; 19,000 die every day from preventable causes 18% 1% 2% 2% 5%
More informationUpdate on Implementation of NUV. Carsten Mantel WHO/FCH/IVB/EPI
Update on Implementation of NUV Carsten Mantel WHO/FCH/IVB/EPI Introduction of New Vaccines The continuum of activity REGULATORY NORMS & STANDARDS VACCINE SUPPLY PROCUREMENT PRICING FINANCING SURVEILLANCE
More informationUNICEF IPV Tender: Demand Forecast UNICEF Bidder s Conference WHO, Geneva 11 October 2013
UNICEF IPV Tender: Demand Forecast UNICEF Bidder s Conference WHO, Geneva 11 October 2013 1 Overview of forecast To inform financial resource requirements, Supply and Procurement Roadmap development and
More informationTotal population 20,675,000. Live births (LB) 349,715. Children <1 year 346,253. Children <5 years 1,778,050. Children <15 years 5,210,100
Sri Lanka 4 Immunization system highlights There is a comprehensive multi-year plan (cmyp) for immunization system strengthening covering -6. A national policy on immunization has been developed. A standing
More informationHealth Challenges and their Determinants in the EMR/MENA
Health Challenges and their Determinants in the EMR/MENA Sameen Siddiqi, Regional Adviser, Health Policy and Planning, WHO EMRO The Middle East and North Africa Health Policy Forum Conference on Better
More informationLast mile vaccine distribution to rural health centres. Faheem Merchant
Last mile vaccine distribution to rural health centres Faheem Merchant New Global Immunization Goals 2000 - Millennium Development Goal # 4 Reduce under 5 child mortality by 2/3 between 1990 and 2015.
More informationTotal population 1,265,308,000. Live births (LB) 27,016,000. Children <1 year 25,928,200. Children <5 years 23,818,000. Children <15 years 25,639,000
India 4 Immunization system highlights There is a comprehensive multiyear plan (cmyp) for immunization covering 3-7. National technical advisory group on immunization (NTAGI) exists and formal written
More informationInaugural Keynote Lecture: Contributions of Gavi and DCVMN to the global vaccine markets
Inaugural Keynote Lecture: Contributions of Gavi and DCVMN to the global vaccine markets Seth Berkley M.D, CEO, Seoul www.gavi.org 1 Gavi s mission, model and achievements to date Gavi s mission Saving
More informationTargeted Diseases and Immunization. Strategic plan
Targeted Diseases and Immunization Strategic plan 2008-2013 Communicable Diseases Unit WHO Regional Office for Europe Mission To provide technical support to WHO European Region Member States to ensure
More informationTable 1: Basic information 2017
EPI history EPI launched in 978 OPV and MCV introduced in 987 AD syringes introduced in 00 HepB vaccine introduced in 003 MCV introduced partially in 008 and made available nationwide in 0 DTP-Hib-HepB
More informationMOBILISING COMMUNITIES FOR IMMUNIZATION SERVICES
MOBILISING COMMUNITIES FOR IMMUNIZATION SERVICES Photo of VHT conducting a community meeting What VHTs and community mobilisers need to know and do Printed with support from UNICEF and partners 2 1. Introduction
More informationNO MORE MISSED MDG4 OPPORTUNITIES: OPTIMIZING EXISTING HEALTH PLATFORMS FOR CHILD SURVIVAL. Measles & Rubella Campaigns
NO MORE MISSED MDG4 OPPORTUNITIES: OPTIMIZING EXISTING HEALTH PLATFORMS FOR CHILD SURVIVAL Measles & Rubella Campaigns With fewer than 600 days remaining to the Millennium Development Goal (MDG) deadline,
More informationVaccine Innovation: Challenges and Opportunities to Protect Health. Julie Louise Gerberding, M.D., M.P.H President, Merck Vaccines
Vaccine Innovation: Challenges and Opportunities to Protect Health Julie Louise Gerberding, M.D., M.P.H President, Merck Vaccines Protecting Health with Vaccines HEALTH IMPROVEMENT Population Impact Guidelines
More informationCountdown to 2015: What Afghanistan wants to achieve
Countdown to 2015: What Afghanistan wants to achieve Dr. SM Moazzem Hossain MD MPH MBA Chief of Health and Nutrition Section UNICEF ACO and Member Secretary Afghanistan Count Down Working Group (ACDWG)
More information1. The World Bank-GAVI Partnership and the Purpose of the Review
1. The World Bank-GAVI Partnership and the Purpose of the Review 1.1 The new World Bank Group strategy makes a strong case for an expanded World Bank Group role in global and regional dialogue and collective
More informationProgress report on. Achievement of the Millennium Development Goals relating to maternal and child health
Regional Committee for the EM/RC52/INF.DOC.4 Eastern Mediterranean July 2005 Fifty-second Session Original: Arabic Agenda item 4 (d) Progress report on Achievement of the Millennium Development Goals relating
More informationGAVI Alliance. Aurelia Nguyen, Director Policy & Market Shaping. IPC Meeting 30 May 2013
GAVI Alliance Aurelia Nguyen, Director Policy & Market Shaping IPC Meeting 30 May 2013 GAVI Update GAVI Alliance Overview 4 Strategic Goals 3 Market Shaping Objectives GAVI Supported Vaccines Critical
More informationMETHODOLOGY & DATA AVAILABILITY
Pneumonia & Diarrhea Progress Report 2018 TABLE OF CONTENTS PAGES 02 03 05 06 FOREWORD EXECUTIVE SUMMARY INTRODUCTION METHODOLOGY & DATA AVAILABILITY Identifying high-burden countries GAPPD intervention
More informationImmunizations are among the most cost effective and widely used public health interventions.
Focused Issue of This Month Recommended by the Korean Pediatric Society, 2008 Hoan Jong Lee, MD Department of Pediatrics, Seoul National University College of Medicine E mail : hoanlee@snu.ac.kr J Korean
More informationTowards the Achievement of GHSA 2024 s Overarching Targets
정보화파트업무계획 [GHSA] Immunization Towards the Achievement of GHSA 2024 s Overarching Targets 2016년추진업무및 2017년업무계획 ( 사업관리 ) 7 th November 2018 Korea Centers for Disease Control and Prevention I. Overview Contents
More informationECONOMICS OF THE VACCINE MARKET: SIZE, GROWTH AND REVENUES
ECONOMICS OF THE VACCINE MARKET: SIZE, GROWTH AND REVENUES 1 Relationship between research funding and burden of disease Source: Global Forum for Health Research Monitoring Financial Flows for Health Research
More informationWhy GAVI Needs to Do More To Ensure Lower Vaccine Prices And How It Could Be Done
Why GAVI Needs to Do More To Ensure Lower Vaccine Prices And How It Could Be Done Vaccines are widely considered a highly cost-effective public health intervention. Médecins Sans Frontières (MSF) is actively
More informationGAVI Role in IPV Introductions
GAVI Role in IPV Introductions Melissa Malhame 12 th WHO/UNICEF Consultation with OPV/IPV Manufacturers and National Regulatory Authorities Geneva, Switzerland, 10 GAVI vaccine support Currently supported
More informationUNICEF s perspective. WHO Informal Consultation to develop further guidance on vaccines for the UNEP-convened INC4 Geneva, 3-4 April 2012
UNICEF s perspective WHO Informal Consultation to develop further guidance on vaccines for the UNEP-convened INC4 Geneva, 3-4 April 2012 UNICEF procures immunization supplies on behalf of around 100 countries
More informationChallenges of building a new vaccine delivery platform for LMICs
Challenges of building a new vaccine delivery platform for LMICs Terri B. Hyde, MD MPH Immunizations Systems Branch, GID, CDC 23 March 2017 Immunization in the Elderly Geneva, Switzerland What has been
More informationExercise: Estimating immunization program costs (~60 minutes)
Exercise: Estimating immunization program costs (~60 minutes) Overview Information on the cost of procuring vaccines and of running national immunization program is a key factor in planning and managing
More informationMonitoring results: goals, strategic objectives and indicators
page 108 Monitoring results: goals, strategic objectives and indicators 6. SURVEILLANCE Strategic Objective 4: strong immunization sytems are an integral part of a well-functioning health system. Indicator
More informationVaccine Security UNICEF Vaccine Procurement Overview. Supplier meeting UNICEF Supply Division 3-4 April 2008 Rob Matthews
Vaccine Security UNICEF Vaccine Procurement Overview Supplier meeting UNICEF Supply Division 3-4 April 28 Rob Matthews UNICEF procures immunization supplies on behalf of around 8-1 countries annually in
More informationProspective Models for Vaccine Procurement and Security in National Immunization Programmes;
Prospective Models for Vaccine Procurement and Security in National Immunization Programmes; Sri Lankan Experience Dr. Sudath Peiris, Immuinization Programme Manager, Sri Lanka Achievements and strengths
More informationPerspectives on Ensuring Access to Vaccines in Lower Income Countries
Perspectives on Ensuring Access to Vaccines in Lower Income Countries Greg Widmyer Deputy Director, Vaccine Delivery Foundation Merieux January 20, 2015 Bill & Melinda Gates Foundation BMGF GLOBAL PROGRAMS
More information